Developer docs
API playgroundTry for free, no card

Search company profiles

Landmark Bio

Full company profile

uuid0007t44

Namestring
Landmark Bio
Legal namestring
Landmark Bio LLC
Websiteurl
landmarkbio.com
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Landmark Bio is an advanced therapy contract development and manufacturing organization (CDMO) headquartered in Watertown, Massachusetts, operating from a 44,000-square-foot integrated facility housing ISO 7 and ISO 8 GMP processing suites, five cell processing suites, two viral vector suites, an mRNA/LNP suite, and a fill & finish suite. The company was founded in 2020 by a consortium that included Harvard, MIT, Cytiva, FUJIFILM Diosynth Biotechnologies, Alexandria Real Estate Equities, and four Boston-area research hospitals (Boston Children's, Dana-Farber, Mass General Brigham, Beth Israel Deaconess). The facility opened in mid-2022, and in 2025 Landmark Bio was acquired by Artis BioSolutions as a wholly-owned entity.

Short descriptiontext

Landmark Bio is an advanced therapy CDMO providing process development, cGMP manufacturing, fill & finish, and CMC regulatory services across viral vectors, cell therapies, nucleic acids, extracellular vesicles, and lipid nanoparticles, serving academic researchers and biopharma clients from its Watertown, MA facility.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersWatertown, United States
HQ citystring
Watertown
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
advanced therapy CDMO, cell therapy manufacturing, gene therapy development, biologics contract manufacturing, viral vector production
Industry5 codes
PRIMARYHLAGABAD
Cell Therapy CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAE
Gene Therapy (Viral Vector/Plasmid) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAAACAJ
Gene Therapy Vector Manufacturing & CDMO Services
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAGAGAA
Cell Therapy CDMO (Autologous/Allogeneic Manufacturing)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAGABAF
mRNA/LNP & Nucleic Acid Therapeutics CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Pharmaceutical Preparations2834
Product category
Cell and Gene Therapy Contract Manufacturing
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Contract Development and Manufacturing Services
TypeProfessional Services
Description

Landmark Bio operates as a CDMO providing fee-for-service contract manufacturing and development services to biotech and pharma companies. Revenue is generated through project-based contracts for process development, analytical development, cGMP manufacturing, fill & finish, and regulatory consulting services.

landmarkbio.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Landmark Bio is an advanced therapy Contract Development and Manufacturing Organization (CDMO) that provides end-to-end services spanning process and analytical development, formulation development, cGMP cell and gene therapy manufacturing, fill and finish, quality control testing, CMC regulatory consulting, and IND-enabling services. The company supports modalities including viral vectors (LVV, AAV), cell therapies (CAR-T, CAR-NK, iPSC, MSC, HSC), nucleic acids, extracellular vesicles, and lipid nanoparticles for biotech, pharma, and academic clients from bench to clinic.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Landmark Bio is an advanced therapy CDMO organized as a platform of interconnected services with modular delivery options. The core offering consists of eight integrated service lines—Process & Analytical Development, Formulation Development, Cell & Gene Therapy Manufacturing, Fill & Finish, Quality Control Testing, CMC Regulatory & Drug Development Consulting, IND-Enabling Services, and Technology Development—that collectively span the full bench-to-clinic journey. These services support five therapeutic modalities: Viral Vectors (LVV, AAV, novel viruses), Cell Therapies (CAR-T, CAR-NK, iPSC, MSC, HSC), Nucleic Acids, Extracellular Vesicles, and Nanoparticles/Non-viral Delivery. The portfolio is anchored by three POSTmarkTM platforms (LVV, AAV, CAR-T) that provide pre-established, scalable manufacturing processes for rapid cGMP adoption. Three flexible partnership models—On-Demand Platforms, Modular Service Offerings, and Joint Innovation—determine how clients engage with these services.

Product and service14 records
1Process & Analytical Development
CategoryCDMO Service
Description

Comprehensive upstream, downstream, cell therapy, viral vector, and non-viral delivery process development plus analytical development services including phase-appropriate method development, qualification, and verification for advanced therapy manufacturers.

2Formulation Development
CategoryCDMO Service
Description

Formulation services for nanomedicines and cell therapies/viral vectors, including rational design of nanoparticle formulations, buffer/excipient composition, cryopreservation parameters, and stability studies.

3Cell & Gene Therapy Manufacturing
CategoryCDMO Service
Description

cGMP manufacturing services for advanced therapies including CAR-T, CAR-NK, iPSC, MSC, HSC, lentiviral vectors, AAV, retroviruses, lipid nanoparticles, and extracellular vesicles, performed in purpose-built modular ISO 7 and ISO 8 processing suites.

4Fill & Finish
CategoryCDMO Service
Description

Aseptic fill and finish processing using Crystal M1 filling station and Cytiva Microcell robotic isolator for pharmaceutical vial filling of advanced therapy drug products.

5Quality Control Testing
CategoryCDMO Service
Description

Comprehensive QC testing services including DNA/RNA quantitation (ddPCR, qPCR), automated cell counters, flow cytometry, HPLC, sterility and endotoxin testing, and full release testing for cell and gene therapies.

6CMC Regulatory & Drug Development Consulting
CategoryConsulting Service
Description

Regulatory and CMC consulting services including target product profiles, process and product characterization, critical process parameters, regulatory risk assessment, CTD Module 3 preparation, and health authority interactions.

7IND-Enabling Services
CategoryCDMO Service
Description

Bespoke CMC work packages to accelerate programs into the clinic, including non-GMP material supply, process development, analytical development, GMP material supply, and regulatory support for IND submission and approval.

8Technology Development
CategoryCDMO Service
Description

Technology development services leveraging academic and industry partnerships to translate groundbreaking research into advanced therapies, including product prototyping, optimization, and novel modality development.

9Viral Vectors Modality Services
CategoryTherapeutic Modality
Description

Manufacturing and development services for lentiviral vectors (LVV), adeno-associated virus (AAV), and novel viral vectors for gene therapy applications.

10Cell Therapies Modality Services
CategoryTherapeutic Modality
Description

Development and cGMP manufacturing services for CAR-T, CAR-NK, iPSC, MSC, HSC, and novel cell therapies for oncology, regenerative medicine, autoimmune disease, and rare disease applications.

11Nucleic Acids Modality Services
CategoryTherapeutic Modality
Description

Services for nucleic acid-based therapeutics including rational particle design and formulation, process and analytical development, and GMP manufacturing for diverse nucleic acid compositions.

12Extracellular Vesicles (EVs) Modality Services
CategoryTherapeutic Modality
Description

Optimization and manufacturing services for extracellular vesicle therapies, including cell line engineering, cargo loading, scalable production (fed batch and continuous perfusion), downstream purification, and lot release testing.

13Nanoparticles & Non-viral Delivery Modality Services
CategoryTherapeutic Modality
Description

Development and manufacturing services for nanoparticle-based therapies including lipid nanoparticles (LNPs), inorganic nanoparticles, formulation development, and physio-chemical characterization.

14Flexible Partnership Models
CategoryEngagement Model
Description

Three engagement models offered to clients: On-Demand Platforms leveraging validated production platforms, Modular Service Offerings for process transfer to GMP facility, and Joint Innovation packages spanning preclinical through commercialization.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership12 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-01-01
Description

Harvard, along with MIT, was an academic founding partner of Landmark Bio. The partnership provides access to groundbreaking research and enables translation of academic discoveries into clinical therapies. Harvard Stem Cell Institute and Harvard Medical School contribute scientific expertise through the Science & Technology Advisory Committee.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-01-01
Description

MIT, along with Harvard, was an academic founding partner of Landmark Bio. MIT Center for Biomedical Innovation (CBI) provides scientific leadership including Executive Director Stacy Springs who chairs Landmark Bio's Science and Technology Committee.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-01-01
Description

Cytiva was an industrial founding partner of Landmark Bio, providing state-of-the-art technologies and capabilities. Chief Technology Officer Beate Mueller-Tiemann serves on the Science and Technology Advisory Committee.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-01-01
Description

FUJIFILM Diosynth Biotechnologies was an industrial founding partner of Landmark Bio. Chief Science Officer Andy Topping serves on the Science and Technology Advisory Committee, contributing expertise in contract development and manufacturing of biologics.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-01-01
Description

Boston Children's Hospital was among Boston's leading hospitals that formed the founding consortium to accelerate life sciences innovations.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-01-01
Description

Dana-Farber Cancer Institute was among Boston's leading hospitals that formed the founding consortium to accelerate life sciences innovations.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-01-01
Description

Mass General Brigham was among Boston's leading hospitals that formed the founding consortium to accelerate life sciences innovations.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-01-01
Description

Beth Israel Deaconess Medical Center was among Boston's leading hospitals that formed the founding consortium to accelerate life sciences innovations.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

NIIMBL (National Institute for Innovation in Manufacturing Biopharmaceuticals) is a U.S. public-private partnership focused on biopharmaceutical manufacturing innovation. Landmark Bio participates in consortium projects including work with MIT, EMD Millipore, and Virica Biotech to reduce empty viral capsids in AAV production. Landmark Bio also received NIIMBL grants with ChromaTan for intensified AAV production.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Landmark Bio and ChromaTan were awarded a NIIMBL grant to develop a scalable and cost-effective process for manufacturing AAV-based gene therapy vectors, leveraging advanced technologies to improve purification efficiency and reduce costs.

Strategic tierMajorTypeImplementation/ SI/ Consulting Partner
Description

EverGlade Consulting supported Landmark Bio in securing up to $18.3 million in ARPA-H funding through the TRANSFORM-EV program. EverGlade guided Landmark Bio through the federal funding process, including negotiations, project structuring, and financial planning for the three-year extracellular vesicle manufacturing platform project.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Artis BioSolutions, a San Diego-based advanced-therapies development and manufacturing company, acquired Landmark Bio in 2025 as a wholly-owned entity. The acquisition integrates Landmark Bio's U.S. platform with Artis' existing capabilities, creating a combined offering for advanced-therapy developers globally.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight2 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Technology-focused biopharmaceutical CDMO building capacity across biologics, viral vectors, and cell therapies. An emerging scaled competitor with overlapping modalities to Landmark Bio's portfolio.

TypeBroad incumbent
Description

Operates one of the world's largest CDMO networks (Patheon) including viral vector and cell therapy services. A scaled incumbent competing for advanced therapy contracts with broader portfolio reach than Landmark Bio.

TypeDirect peer
Description

Global CDMO offering cell and gene therapy, viral vector, and biologics manufacturing services with GMP facilities across multiple geographies. Closely comparable mid-to-large advanced therapy CDMO competitor.

TypeDirect peer
Description

Specializes in plasmid DNA, mRNA, and viral vector manufacturing for gene and cell therapies (now part of Danaher). Directly competes with Landmark Bio in viral vector and nucleic acid CDMO services.

TypeDirect peer
Description

Global leader in cell and gene therapy CDMO services, offering process development, GMP manufacturing, and fill & finish across viral vectors, cell therapies, and biologics. Direct competitor to Landmark Bio across nearly every modality it serves.

TypeDirect peer
Description

Large-scale CDMO with deep viral vector, gene therapy, and biologics manufacturing capabilities. Both a founding industrial partner and a direct competitor to Landmark Bio in the CDMO market.

TypeBroad incumbent
Description

Large-scale contract manufacturer expanding into advanced therapies and gene therapy. Serves similar biopharma customers with broader capacity but less specialization in autologous cell therapies.

8Vineti
TypeEmerging player
Description

Specialized cell and gene therapy orchestration platform providing chain-of-custody, manufacturing workflow, and logistics software. Comparable as an emerging ecosystem enabler for cell therapy commercialization adjacent to Landmark Bio's manufacturing services.

TypeDirect peer
Description

Major CDMO with significant advanced therapy capabilities in cell therapy, viral vectors, and biologics manufacturing (now owned by Novo Holdings). Competes head-to-head with Landmark Bio for biotech and biopharma development and manufacturing contracts.

TypeDirect peer
Description

Provides CDMO services including cell and gene therapy manufacturing, viral vector production, and biologics testing. Overlaps directly with Landmark Bio's process development, GMP manufacturing, and QC offerings.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Landmark Bio

Cell and Gene Therapy Contract Manufacturinglandmarkbio.com

Landmark Bio is an advanced therapy CDMO providing process development, cGMP manufacturing, fill & finish, and CMC regulatory services across viral vectors, cell therapies, nucleic acids, extracellular vesicles, and lipid nanoparticles, serving academic researchers and biopharma clients from its Watertown, MA facility.

What Landmark Bio does

Landmark Bio is an advanced therapy contract development and manufacturing organization (CDMO) headquartered in Watertown, Massachusetts, operating from a 44,000-square-foot integrated facility housing ISO 7 and ISO 8 GMP processing suites, five cell processing suites, two viral vector suites, an mRNA/LNP suite, and a fill & finish suite. The company was founded in 2020 by a consortium that included Harvard, MIT, Cytiva, FUJIFILM Diosynth Biotechnologies, Alexandria Real Estate Equities, and four Boston-area research hospitals (Boston Children's, Dana-Farber, Mass General Brigham, Beth Israel Deaconess). The facility opened in mid-2022, and in 2025 Landmark Bio was acquired by Artis BioSolutions as a wholly-owned entity.

Landmark Bio firmographics

Firmographics
Name
Landmark Bio
Legal name
Landmark Bio LLC
Website
https://landmarkbio.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
11–50 employees
Short description
Landmark Bio is an advanced therapy CDMO providing process development, cGMP manufacturing, fill & finish, and CMC regulatory services across viral vectors, cell therapies, nucleic acids, extracellular vesicles, and lipid nanoparticles, serving academic researchers and biopharma clients from its Watertown, MA facility.
Ownership category
akta.pro rank

Landmark Bio industry classification

Industry
Product category
Cell and Gene Therapy Contract Manufacturing
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Services-Commercial Physical & Biological Research (8731), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAGABAD
Cell Therapy CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAE
Gene Therapy (Viral Vector/Plasmid) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAAACAJ
Gene Therapy Vector Manufacturing & CDMO Services
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAGAGAA
Cell Therapy CDMO (Autologous/Allogeneic Manufacturing)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAGABAF
mRNA/LNP & Nucleic Acid Therapeutics CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Advanced therapy CDMO
  • Cell therapy manufacturing
  • Gene therapy development
  • Biologics contract manufacturing
  • Viral vector production

Where Landmark Bio is headquartered

Location

Headquarters

HQ city
Watertown
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Landmark Bio business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain

Revenue model

  1. Contract Development and Manufacturing Services: Landmark Bio operates as a CDMO providing fee-for-service contract manufacturing and development services to biotech and pharma companies. Revenue is generated through project-based contracts for process development, analytical development, cGMP manufacturing, fill & finish, and regulatory consulting services.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Landmark Bio product offering

Product offering

Core offering

Landmark Bio is an advanced therapy Contract Development and Manufacturing Organization (CDMO) that provides end-to-end services spanning process and analytical development, formulation development, cGMP cell and gene therapy manufacturing, fill and finish, quality control testing, CMC regulatory consulting, and IND-enabling services. The company supports modalities including viral vectors (LVV, AAV), cell therapies (CAR-T, CAR-NK, iPSC, MSC, HSC), nucleic acids, extracellular vesicles, and lipid nanoparticles for biotech, pharma, and academic clients from bench to clinic.

Product overview

Landmark Bio is an advanced therapy CDMO organized as a platform of interconnected services with modular delivery options. The core offering consists of eight integrated service lines—Process & Analytical Development, Formulation Development, Cell & Gene Therapy Manufacturing, Fill & Finish, Quality Control Testing, CMC Regulatory & Drug Development Consulting, IND-Enabling Services, and Technology Development—that collectively span the full bench-to-clinic journey. These services support five therapeutic modalities: Viral Vectors (LVV, AAV, novel viruses), Cell Therapies (CAR-T, CAR-NK, iPSC, MSC, HSC), Nucleic Acids, Extracellular Vesicles, and Nanoparticles/Non-viral Delivery. The portfolio is anchored by three POSTmarkTM platforms (LVV, AAV, CAR-T) that provide pre-established, scalable manufacturing processes for rapid cGMP adoption. Three flexible partnership models—On-Demand Platforms, Modular Service Offerings, and Joint Innovation—determine how clients engage with these services.

Differentiator

Problem solved

Functional benefit

Products and services

  • Process & Analytical Development Comprehensive upstream, downstream, cell therapy, viral vector, and non-viral delivery process development plus analytical development services including phase-appropriate method development, qualification, and verification for advanced therapy manufacturers.
  • Formulation Development Formulation services for nanomedicines and cell therapies/viral vectors, including rational design of nanoparticle formulations, buffer/excipient composition, cryopreservation parameters, and stability studies.
  • Cell & Gene Therapy Manufacturing cGMP manufacturing services for advanced therapies including CAR-T, CAR-NK, iPSC, MSC, HSC, lentiviral vectors, AAV, retroviruses, lipid nanoparticles, and extracellular vesicles, performed in purpose-built modular ISO 7 and ISO 8 processing suites.
  • Fill & Finish Aseptic fill and finish processing using Crystal M1 filling station and Cytiva Microcell robotic isolator for pharmaceutical vial filling of advanced therapy drug products.
  • Quality Control Testing Comprehensive QC testing services including DNA/RNA quantitation (ddPCR, qPCR), automated cell counters, flow cytometry, HPLC, sterility and endotoxin testing, and full release testing for cell and gene therapies.
  • CMC Regulatory & Drug Development Consulting Regulatory and CMC consulting services including target product profiles, process and product characterization, critical process parameters, regulatory risk assessment, CTD Module 3 preparation, and health authority interactions.
  • IND-Enabling Services Bespoke CMC work packages to accelerate programs into the clinic, including non-GMP material supply, process development, analytical development, GMP material supply, and regulatory support for IND submission and approval.
  • Technology Development Technology development services leveraging academic and industry partnerships to translate groundbreaking research into advanced therapies, including product prototyping, optimization, and novel modality development.
  • Viral Vectors Modality Services Manufacturing and development services for lentiviral vectors (LVV), adeno-associated virus (AAV), and novel viral vectors for gene therapy applications.
  • Cell Therapies Modality Services Development and cGMP manufacturing services for CAR-T, CAR-NK, iPSC, MSC, HSC, and novel cell therapies for oncology, regenerative medicine, autoimmune disease, and rare disease applications.
  • Nucleic Acids Modality Services Services for nucleic acid-based therapeutics including rational particle design and formulation, process and analytical development, and GMP manufacturing for diverse nucleic acid compositions.
  • Extracellular Vesicles (EVs) Modality Services Optimization and manufacturing services for extracellular vesicle therapies, including cell line engineering, cargo loading, scalable production (fed batch and continuous perfusion), downstream purification, and lot release testing.
  • Nanoparticles & Non-viral Delivery Modality Services Development and manufacturing services for nanoparticle-based therapies including lipid nanoparticles (LNPs), inorganic nanoparticles, formulation development, and physio-chemical characterization.
  • Flexible Partnership Models Three engagement models offered to clients: On-Demand Platforms leveraging validated production platforms, Modular Service Offerings for process transfer to GMP facility, and Joint Innovation packages spanning preclinical through commercialization.

Companies that use Landmark Bio

Customer profile

Segments2 records

Ideal customer profiles2 records

Landmark Bio technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Landmark Bio partnerships and signals

Strategic signal

Partnerships

Twelve partnerships are on record, tiered core and major.

  • Harvard UniversitycoreStrategic or Co-development Partner · 1 January 2020Harvard, along with MIT, was an academic founding partner of Landmark Bio. The partnership provides access to groundbreaking research and enables translation of academic discoveries into clinical therapies. Harvard Stem Cell Institute and Harvard Medical School contribute scientific expertise through the Science & Technology Advisory Committee.
  • Massachusetts Institute of Technology (MIT)coreStrategic or Co-development Partner · 1 January 2020MIT, along with Harvard, was an academic founding partner of Landmark Bio. MIT Center for Biomedical Innovation (CBI) provides scientific leadership including Executive Director Stacy Springs who chairs Landmark Bio's Science and Technology Committee.
  • CytivacoreStrategic or Co-development Partner · 1 January 2020Cytiva was an industrial founding partner of Landmark Bio, providing state-of-the-art technologies and capabilities. Chief Technology Officer Beate Mueller-Tiemann serves on the Science and Technology Advisory Committee.
  • FUJIFILM Diosynth BiotechnologiescoreStrategic or Co-development Partner · 1 January 2020FUJIFILM Diosynth Biotechnologies was an industrial founding partner of Landmark Bio. Chief Science Officer Andy Topping serves on the Science and Technology Advisory Committee, contributing expertise in contract development and manufacturing of biologics.
  • Boston Children's HospitalcoreStrategic or Co-development Partner · 1 January 2020Boston Children's Hospital was among Boston's leading hospitals that formed the founding consortium to accelerate life sciences innovations.
  • Dana-Farber Cancer InstitutecoreStrategic or Co-development Partner · 1 January 2020Dana-Farber Cancer Institute was among Boston's leading hospitals that formed the founding consortium to accelerate life sciences innovations.
  • Mass General BrighamcoreStrategic or Co-development Partner · 1 January 2020Mass General Brigham was among Boston's leading hospitals that formed the founding consortium to accelerate life sciences innovations.
  • Beth Israel Deaconess Medical CentercoreStrategic or Co-development Partner · 1 January 2020Beth Israel Deaconess Medical Center was among Boston's leading hospitals that formed the founding consortium to accelerate life sciences innovations.
  • NIIMBLmajorStrategic or Co-development PartnerNIIMBL (National Institute for Innovation in Manufacturing Biopharmaceuticals) is a U.S. public-private partnership focused on biopharmaceutical manufacturing innovation. Landmark Bio participates in consortium projects including work with MIT, EMD Millipore, and Virica Biotech to reduce empty viral capsids in AAV production. Landmark Bio also received NIIMBL grants with ChromaTan for intensified AAV production.
  • ChromaTan Inc.majorStrategic or Co-development PartnerLandmark Bio and ChromaTan were awarded a NIIMBL grant to develop a scalable and cost-effective process for manufacturing AAV-based gene therapy vectors, leveraging advanced technologies to improve purification efficiency and reduce costs.
  • EverGlade ConsultingmajorImplementation/ SI/ Consulting PartnerEverGlade Consulting supported Landmark Bio in securing up to $18.3 million in ARPA-H funding through the TRANSFORM-EV program. EverGlade guided Landmark Bio through the federal funding process, including negotiations, project structuring, and financial planning for the three-year extracellular vesicle manufacturing platform project.
  • Artis BioSolutionscoreStrategic or Co-development PartnerArtis BioSolutions, a San Diego-based advanced-therapies development and manufacturing company, acquired Landmark Bio in 2025 as a wholly-owned entity. The acquisition integrates Landmark Bio's U.S. platform with Artis' existing capabilities, creating a combined offering for advanced-therapy developers globally.

Scale indicators6 records

Recent moves9 records

Expansion highlights2 records

Landmark Bio competitors and assessment

Company assessment

Emerging players

  • Resilience: Technology-focused biopharmaceutical CDMO building capacity across biologics, viral vectors, and cell therapies. An emerging scaled competitor with overlapping modalities to Landmark Bio's portfolio.
  • Vineti: Specialized cell and gene therapy orchestration platform providing chain-of-custody, manufacturing workflow, and logistics software. Comparable as an emerging ecosystem enabler for cell therapy commercialization adjacent to Landmark Bio's manufacturing services.

Broad incumbents

  • Thermo Fisher Scientific: Operates one of the world's largest CDMO networks (Patheon) including viral vector and cell therapy services. A scaled incumbent competing for advanced therapy contracts with broader portfolio reach than Landmark Bio.
  • Samsung Biologics: Large-scale contract manufacturer expanding into advanced therapies and gene therapy. Serves similar biopharma customers with broader capacity but less specialization in autologous cell therapies.

Direct peers

  • AGC Biologics: Global CDMO offering cell and gene therapy, viral vector, and biologics manufacturing services with GMP facilities across multiple geographies. Closely comparable mid-to-large advanced therapy CDMO competitor.
  • Aldevron: Specializes in plasmid DNA, mRNA, and viral vector manufacturing for gene and cell therapies (now part of Danaher). Directly competes with Landmark Bio in viral vector and nucleic acid CDMO services.
  • Lonza: Global leader in cell and gene therapy CDMO services, offering process development, GMP manufacturing, and fill & finish across viral vectors, cell therapies, and biologics. Direct competitor to Landmark Bio across nearly every modality it serves.
  • FUJIFILM Diosynth Biotechnologies: Large-scale CDMO with deep viral vector, gene therapy, and biologics manufacturing capabilities. Both a founding industrial partner and a direct competitor to Landmark Bio in the CDMO market.
  • Catalent: Major CDMO with significant advanced therapy capabilities in cell therapy, viral vectors, and biologics manufacturing (now owned by Novo Holdings). Competes head-to-head with Landmark Bio for biotech and biopharma development and manufacturing contracts.
  • Charles River Laboratories: Provides CDMO services including cell and gene therapy manufacturing, viral vector production, and biologics testing. Overlaps directly with Landmark Bio's process development, GMP manufacturing, and QC offerings.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Landmark Bio social profiles

Digital presence

Landmark Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Landmark Bio leadership team

Management profile

Number of profiles

Profiles6 records

Landmark Bio funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Landmark Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Landmark Bio

What does Landmark Bio do?

Landmark Bio is an advanced therapy Contract Development and Manufacturing Organization (CDMO) that provides end-to-end services spanning process and analytical development, formulation development, cGMP cell and gene therapy manufacturing, fill and finish, quality control testing, CMC regulatory consulting, and IND-enabling services. The company supports modalities including viral vectors (LVV, AAV), cell therapies (CAR-T, CAR-NK, iPSC, MSC, HSC), nucleic acids, extracellular vesicles, and lipid nanoparticles for biotech, pharma, and academic clients from bench to clinic.

Is Landmark Bio a public or private company?

Landmark Bio is a private company. It is classified as corporate owned and is currently operating.

When was Landmark Bio founded?

Landmark Bio was founded in 2020. It employs 11 to 50 people.

Where is Landmark Bio based?

Landmark Bio is headquartered in Watertown, United States, in the North America region.

How does Landmark Bio make money?

One revenue line is on record: contract Development and Manufacturing Services.

Who are Landmark Bio's main competitors?

Emerging players on record are Resilience and Vineti. Broad incumbents are Thermo Fisher Scientific and Samsung Biologics. Direct peers are AGC Biologics, Aldevron, Lonza, FUJIFILM Diosynth Biotechnologies, Catalent and Charles River Laboratories.

Does Landmark Bio have an API?

No public API is recorded for Landmark Bio.

What industry is Landmark Bio in?

Landmark Bio's product category is Cell and Gene Therapy Contract Manufacturing. Its primary akta.pro industry code is HLAGABAD, Cell Therapy CDMO, with a secondary code of HLAGABAE, Gene Therapy (Viral Vector/Plasmid) CDMO. Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FinancialContent Business PageLandmark Bio and Syngoi Technologies to Operate as Artis BioSolutions, an End-to-end Gene-to-GMP Platform for Genetic MedicinesArtis BioSolutions announced that Landmark Bio (Watertown, Massachusetts) and Syngoi (Bilbao, Spain) will now operate under a unified Artis BioSolutions brand, completing a transatlantic platform that connects synthetic DNA production with downstream development and GMP manufacturing for genetic medicines. The company, which secured a $18.3 million award from ARPA-H in April for the TRANSFORM EV project on scalable continuous manufacturing for extracellular vesicle therapies, is positioning itself as a single integrated alternative to fragmented supply chains in the advanced therapy industry. Artis BioSolutions is based in San Diego and operates production sites in both the United States and Spain.GenengnewsNIIMBL to Support Vector Production and AI-Ready Training ProjectsNIIMBL, a U.S. public-private partnership focused on biopharmaceutical manufacturing innovation, announced 39 funding awards to support domestic production and talent development. Several projects focus on improving adeno-associated viral vector production for gene therapy, including work by Michigan Technological University, North Carolina State, and an MIT-led consortium with EMD Millipore, Landmark Bio, and Virica Biotech to reduce empty viral capsids. Additional initiatives include workforce training programs such as Texas A&M University's NeuroPipes program for neurodiverse adults and the Wistar Institute's BioPATH national consortium focused on biomanufacturing, AI, and automation.Pulse 2.0EverGlade: $18.3 Million ARPA-H Funding Secured For Landmark Bio To Advance EV ManufacturingEverGlade Consulting supported Landmark Bio in securing up to $18.3 million in funding from the Advanced Research Projects Agency for Health (ARPA-H) under its TRANSFORM-EV program. The three-year project will fund development of a scalable continuous manufacturing platform for extracellular vesicles, replacing low-yield, high-cost batch production methods with the goal of expanding global access to EV-based therapeutics and similar next-generation treatments. EverGlade guided Landmark Bio through the federal funding process, including negotiations, project structuring, and financial planning.AllsciLandmark Bio secures USD 18.3m ARPA-H funding for extracellular vesicle manufacturingLandmark Bio, a contract development and manufacturing organization based in Watertown, Massachusetts, has secured up to USD 18.3 million in non-dilutive federal funding through the Advanced Research Projects Agency for Health (ARPA-H) TRANSFORM-EV program. The three-year award will support development of a continuous manufacturing platform for extracellular vesicles, a therapeutic modality that has faced scalability constraints due to current low-yield, high-cost batch production methods. The funding represents the largest single disclosed funding event in Landmark Bio's history, with the company supported during negotiations by advisory firm EverGlade.PR NewswireEVERGLADE HELPS LANDMARK BIO SECURE UP TO $18.3 MILLION IN ARPA-H FUNDINGEverGlade, a national advisory firm, successfully supported Landmark Bio through negotiations to secure up to $18.3 million in funding from ARPA-H through its TRANSFORM-EV program. The three-year project will enable Landmark Bio to develop an efficient and scalable continuous manufacturing platform for extracellular vesicles, aiming to overcome current low-yield, high-cost batch methods and broaden patient access to EV-based and similar therapeutics worldwide.MorningstarEVERGLADE HELPS LANDMARK BIO SECURE UP TO $18.3 MILLION IN ARPA-H FUNDINGEverGlade, a national advisory firm, successfully supported Landmark Bio through negotiations to secure up to $18.3 million in ARPA-H funding through the TRANSFORM-EV program. The three-year award will fund development of a scalable continuous manufacturing platform for extracellular vesicles to overcome current low-yield, high-cost batch methods, with the goal of broadening patient access to EV-based and similar advanced therapeutics like viral vectors and cell therapies worldwide.Business Wire BlogLandmark Bio Secures Up to $18.3 Million ARPA-H Award to Build a Scalable Continuous Manufacturing Platform for Extracellular Vesicle TherapiesLandmark Bio secured an ARPA-H award of up to $18.3 million to build a scalable continuous manufacturing platform for extracellular vesicle therapies. The project aims to reduce manufacturing footprint, costs, and lead time by up to 10x, with work led by Landmark Bio and MIT. The company expects to apply insights to support partners in EV programs.Harvard GazetteAdvanced Therapies RFPHarvard University researchers have been offered a funding opportunity to support projects at Landmark Bio, which focuses on developing therapeutic candidates and evaluating advanced therapy technologies. This initiative aims to address the challenges in pharmaceutical development, specifically in translating lab protocols to manufacturing processes that comply with Good Manufacturing Practices. The collaboration involves several prominent institutions to facilitate the transition from research to clinical applications of advanced therapies.YahooLandmark Bio Forges New Collaboration to Accelerate Early-Stage Translational Cell and Gene TherapiesLandmark Bio announced a new collaboration with Mass General Brigham to provide development and manufacturing services for cell and gene therapies originating from the health system. The agreement enables early-stage translational research and development through Mass General Brigham's Gene and Cell Therapy Institute, aiming to accelerate therapeutic innovation from bench to bedside.FinSMEsArtis BioSolutions Raises Funding; Acquires Landmark BioArtis BioSolutions raised an undisclosed amount in funding led by Oak HC/FT and acquired Landmark Bio for an undisclosed amount. The company will use the funds to expand its genetic medicine platform and accelerate growth. The acquisition aims to provide end-to-end capabilities for therapy developers.